Difference between revisions of "Crizotinib"
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==See also== | ==See also== | ||
*[[Lung adenocarcinoma]]. | *[[Lung adenocarcinoma]]. | ||
*[[Cancer drugs]]. | |||
==References== | ==References== | ||
Revision as of 19:23, 7 August 2018
Crizotinib a drug used to treat lung cancer.
- Lung cancer with ROS1 rearrangement.[1]
- Lung carcinoma with ALK rearrangement.[2]
- Lung carcinoma with MET amplification.[3]
See also
References
- ↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
- ↑ Wu, YL.; Lu, S.; Lu, Y.; Zhou, J.; Shi, YK.; Sriuranpong, V.; Ho, JCM.; Ong, CK. et al. (Jun 2018). "Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.". J Thorac Oncol. doi:10.1016/j.jtho.2018.06.012. PMID 29966800.
- ↑ Forde, PM.; Rudin, CM. (Jun 2012). "Crizotinib in the treatment of non-small-cell lung cancer.". Expert Opin Pharmacother 13 (8): 1195-201. doi:10.1517/14656566.2012.688029. PMID 22594847.